Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.7 SEK | +1.39% | -0.92% | +6.41% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 21.92M | Sales 2025 * | 343M 31.39M | Capitalization | 1.5B 138M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.34M | Net income 2025 * | -712M -65.23M | EV / Sales 2024 * | 8.27 x |
Net Debt 2024 * | 474M 43.43M | Net Debt 2025 * | 733M 67.19M | EV / Sales 2025 * | 6.53 x |
P/E ratio 2024 * |
-2.37
x | P/E ratio 2025 * |
-2.81
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | +1.39% | ||
1 week | -0.92% | ||
Current month | -4.19% | ||
1 month | -9.42% | ||
3 months | -22.30% | ||
6 months | +15.78% | ||
Current year | +6.41% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 27.88 | +2.05% | 33 961 |
24-04-26 | 27.32 | +0.44% | 257,784 |
24-04-25 | 27.2 | -2.44% | 200,908 |
24-04-24 | 27.88 | -0.29% | 98,780 |
24-04-23 | 27.96 | -0.64% | 98,303 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 06:31 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.41% | 137M | |
+1.51% | 42.75B | |
+48.09% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- HNSA Stock